Since 2022, the UK dental M&A market has seen more than 120 transactions. Independent practices, squeezed by rising costs and recruitment challenges, are attracted to the operational efficiencies and career pathways that larger groups provide.

Bridgepoint’s track record—growing Oris Dental across the Nordics and transforming Oasis Dental into a market leader before its sale to Bupa in 2017—demonstrates how a buy-and-build strategy can scale clinical excellence and drive value.

With mydentist already #1 in revenue and reach, we expect Bridgepoint to accelerate regional roll-ups, standardize protocols and deliver centralized support that independent operators can’t match.

“Bridgepoint’s expertise in scaling provider platforms positions mydentist for accelerated growth,” says Hywel Loveluck, Healthcare Boutique Advisory at ProPractices. “Their track record shows they know how to marry clinical quality with operational rigor.”

Item dDigital dentistry has moved from early adopter novelty to essential investment.

Between 2022 and 2024, intra-oral scanner penetration in UK practices leapt from around 15% to over 40%, slashing treatment times and boosting case acceptance. PE-backed groups that pair scanners with integrated booking platforms, tele-triage and patient portals are reporting 20%+ uplifts in new-patient conversions.

At ProPractices, we believe the next wave will integrate AI-driven diagnostics and outcome analytics—platforms that invest now will secure both margin upside and patient loyalty.escription

While large-cap funds grappled with fundraising headwinds, mid-market healthcare sponsors raised roughly £50 billion between 2022 and 2025—40% more than the prior three-year span.

These firms are posting top-quartile returns by leaning into operational playbooks rather than pure financial engineering. mydentist’s recurring NHS revenues, low capex needs and digital levers make it exactly the kind of platform that outperforms in this cycle.

As lending markets stabilize and dry powder remains elevated, we expect continued activity, but success will come to those who marry rapid add-on M&A with rigorous clinical governance.

Palamon’s 2021 entry and now-5-year-later exit reflect the prevailing 4–5 year hold period for mid-market healthcare assets.

Looking ahead, Bridgepoint will likely plan for a 2028–30 exit—either via strategic sale or continuation fund—once integration synergies and digital ROI fully materialize.

Our advice to sponsors: avoid the temptation to over-leverage. Balancing acquisition pace with sustained quality and compliance will be critical, especially under the CQC’s increasingly stringent inspections and evolving NHS contract metrics.escription

Independent Practices: Watch for more succession deals as owner-operators seek partnerships to fund technology upgrades and recruit associates.

Specialist M&A: Expect bolt-ons in ortho, implants and aesthetics—niche services that broaden revenue streams and patient lifetime value.

Workforce Investments: Groups that allocate at least 10% of EBITDA to training, wellbeing and equity incentives will win the recruitment battle.

Regulatory Readiness: Embedding continuous-improvement compliance teams now will avoid execution drag and protect reputations.

ProPractices Takeaway Bridgepoint’s investment in mydentist exemplifies the 2022–25 mid-market PE blueprint: platform scale, digital transformation and clinician-centric models.

As the UK dental landscape consolidates, sponsors and operators who combine disciplined buy-and-build execution with proactive technology and compliance investments will lead the affordable-care revolution.

For anyone involved in dentistry and healthcare PE, the next 24 months will distinguish market-makers from followers.